glp 1 agonist oral GLP-1-Based Therapeutics in the Obesity–Metabolic Syndrome–Diabetes Continuum: Translational Advances, Clinical Barriers, and Emerging Strategies Small molecule oral GLP-1 agonist

CPAA (2022) 14:1926

Lifestyle: 3045 min post-meal walk, resistance/yoga 34/week, 78 hours sleep, stress management through pranayama, and 2.53 L water daily

GLP-1 receptor agonists can be a powerful tool for diabetes management, but only under close medical supervision

70180 mg/dL) was not inferior in the insulin and pramlintide closed-loop system group, suggesting a possible substitution for carbohydrate counting

Using within-year lookback in the encounter data for Medicare Advantage enrollees means the estimate may be lower than if the same typically longer lookback period for traditional Medicare beneficiaries was used

All methods were performed in accordance with relevant guidelines